Sarepta Therapeutics, Inc. Stock

Equities

SRPT

US8036071004

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-14 EDT 5-day change 1st Jan Change
122.8 USD -1.73% Intraday chart for Sarepta Therapeutics, Inc. -0.39% +27.39%
Sales 2024 * 1.94B 2.66B Sales 2025 * 2.81B 3.86B Capitalization 11.61B 15.94B
Net income 2024 * 307M 421M Net income 2025 * 921M 1.26B EV / Sales 2024 * 5.45 x
Net cash position 2024 * 1.03B 1.42B Net cash position 2025 * 2.54B 3.49B EV / Sales 2025 * 3.22 x
P/E ratio 2024 *
37.3 x
P/E ratio 2025 *
11.8 x
Employees 1,314
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.03%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.73%
1 week-0.39%
Current month-5.41%
1 month-7.40%
3 months-0.74%
6 months+29.96%
Current year+27.39%
More quotes
1 week
118.70
Extreme 118.7
125.89
1 month
109.91
Extreme 109.91
133.12
Current year
91.34
Extreme 91.3439
146.68
1 year
55.25
Extreme 55.25
146.68
3 years
55.25
Extreme 55.25
159.89
5 years
55.25
Extreme 55.25
181.83
10 years
8.00
Extreme 8
181.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 17-06-25
Director of Finance/CFO 48 14-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 61 17-06-25
Chairman 71 09-03-30
Director/Board Member 65 15-06-01
More insiders
Date Price Change Volume
24-06-14 122.8 -1.73% 1,000,340
24-06-13 125 +4.18% 2,162,067
24-06-12 120 -1.15% 701,721
24-06-11 121.4 -0.99% 682,470
24-06-10 122.6 -0.59% 1,636,235

Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm

More quotes
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
122.8 USD
Average target price
167.1 USD
Spread / Average Target
+36.02%
Consensus